CD40 Ligand antibody (PE)

Catalog No. ABIN135218

Product Details anti-CD40 Ligand Antibody (PE)

Target: CD40 Ligand (CD40LG)

Reactivity: Mouse

Host: Hamster

Clonality: Monoclonal

Conjugate: This CD40 Ligand antibody is conjugated to PE

Application: Flow Cytometry (FACS)

Specificity: Mouse CD154, Mr 39 kDa

Characteristics: Hamster Anti-Mouse CD154-PE

Immunogen: Activated mouse Th1 clone D1.6

Clone: MR1

Isotype: IgG

Application Details

Application Notes:

• Applications: FC - Quality tested , IHC-FS - Reported in literature , IP - Reported in literature , Block - Reported in literature , ELISA - Reported in literature
• Working Dilutions: Flow Cytometry FITC and BIOT conjugates 2 g/106 cells PE conjugate 0.2 g/106 cells For flow cytometry, the suggested use of these reagents is in a final volume of 100 L

Comment:

In vivo and in vitro blockage of CD154 function

Sample Volume: 1 mL

Restrictions: For Research Use only

Handling

Concentration: 0.1 mg/mL

Buffer: 0.1 mg in 1.0 mL of PBS/Sodium azide and a stabilizing agent

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Do not freeze!
Protect conjugated products from light.
Each reagent is stable for the period shown on the bottle label if stored as directed.

Storage: 4 °C

Storage Comment: Store at 2-8°C

Target Details for CD40 Ligand

Target: CD40 Ligand (CD40LG)

Alternative Name: CD154 (CD40LG Products)

Background: CD154, formerly known as CD40 ligand and gp39, is a type II integral membrane protein and a member of the tumor necrosis factor (TNF) family of ligands. It is an important accessory molecule in T cell-B cell costimulatory interactions, and is expressed predominantly on activated CD4+ T lymphocytes. It is also present on the surface of activated Th0, Th1, and Th2 T cell clones. Its expression is transient and cyclosporin-sensitive.

Pathways: NF-kappaB Signaling, Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints